Log in to save to my catalogue

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiom...

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiom...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1369715813

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

About this item

Full title

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Publisher

Kidlington: Elsevier

Journal title

The Lancet (British edition), 2013-03, Vol.381 (9869), p.817-824

Language

English

Formats

Publication information

Publisher

Kidlington: Elsevier

More information

Scope and Contents

Contents

Summary Background Angiomyolipomas are slow-growing tumours associated with constitutive activation of mammalian target of rapamycin (mTOR), and are common in patients with tuberous sclerosis complex and sporadic lymphangioleiomyomatosis. The insidious growth of these tumours predisposes patients to serious complications including retroperitoneal h...

Alternative Titles

Full title

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1369715813

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1369715813

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(12)61767-X

How to access this item